UNCY Unicycive Therapeutics, Inc.
Healthcare$7.06-12.62%ClosedMarket Cap: $151.7M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
51.24
P/S
0.00
EV/EBITDA
-3.93
DCF Value
$0.18
FCF Yield
-16.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-131.2%
ROA
-62.0%
ROIC
-77.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-8.4M | $-12.8M | $— | — |
| Q4 null | $0.00 | NaN% | $-7.2M | $-14.7M | $— | — |
| FY null | $0.00 | -Infinity% | $-29.5M | $-26.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-7.3M | $-6.0M | $— | — |
| Q2 null | $0.00 | NaN% | $-7.0M | $-6.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-8.0M | $570.0K | $— | — |
| Q4 null | $0.00 | NaN% | $-9.3M | $-21.5M | $— | — |
| FY null | $0.00 | NaN% | $-32.1M | $-36.7M | $— | — |
| Q3 null | $0.00 | NaN% | $-6.3M | $-4.1M | $— | — |
| Q2 null | $0.00 | NaN% | $-7.4M | $9.9M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-9.2M | $-21.0M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-6.3M | $-7.8M | $-0.22 | — |